HAMILTON, Bermuda, Aug. 24, 2017 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative γδ T cell immunotherapy for the treatment of cancers, today announced the formation of its inaugural Scientific Advisory Board (SAB). The newly formed SAB includes distinguished oncologists and immunologists who will provide perspectives on the research and development of cancer immunotherapies as the Company advances its initial programs for the treatment of leukemia & lymphoma and glioblastoma (GBM) to the clinic.
Inaugural SAB members include (https://www.incysus.com/about):
Dr. Lamb, commented, “Current cell therapy approaches for cancer target specific molecules that are not expressed on the entire tumor, which reduces [the] disease burden, but does not eliminate all tumor cells. The unique feature of γδ T cell cancer immunotherapy is that the cells target surface proteins that are present as a result of a biological process inherent in all cancer cells. We are excited to move this technology forward with the help of an extraordinary group of experts in the growing field of immunotherapy."
Dr. Maus, added, “New strategies for glioblastoma (GBM) are urgently needed, and I am excited to participate in the development and investigation of different T-cell subsets and other novel approaches that could advance the field and help patients.”
"We are honored to welcome these renowned scientists and physicians to our SAB," said William Ho, Chief Executive Officer of Incysus. "Forming a scientific advisory board is another important milestone as we continue to build Incysus into an integrated, immuno-oncology company. The diverse expertise in immunology, gene therapy and oncology will support our goal to bring innovative therapies and new hope to cancer patients and their families."
About Incysus, Ltd.
Incysus is a Bermuda incorporated company focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified γδ T cells, our technology addresses the challenges that immunotherapies face targeting cold, low mutation, cancers. The Company's immuno-oncology programs include activated and gene modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells.